Table 1 Characteristics of the 73 patients with PsA included in the analysis and univariate analysis of predictive factors to achieving a clinically meaningful improvement in HAQ-DI, as defined by MCID > 0.35

1.1—Baseline data

Female n (%)

43 (58.9)

27 (58.7)

16 (59.3)

1.02 (0.55–1.87)

0.962

Age, years mean ± SD

54.3 ± 9.9

56.7 ± 9.1

50.3 ± 10.3

0.96 (0.94–0.98)

0.001

Time of diagnosis in years*

8 (3–15)

7 (3–16)

8 (2–14)

0.99 (0.95–1.03)

0.493

Symptoms duration in years*

12.0 (5–20)

12.5(5–21)

12.0(6–18)

0.99(0.96–1.02)

0.376

White ethnicity n (%)

65 (89.0)

43 (93.5)

22 (81.5)

0.54 (0.29–1.02)

0.058

CRP in mg/dL*

0.6 (0.4–1.6)

0.4 (0.4–1.7)

0.7 (0.4–1.5)

0.96 (0.8–1.15)

0.630

Patient global VAS in cm*

5.3 (3.6–7.3)

5.0 (3.6–7.1)

5.8 (3.6–7.8)

1.09 (0.97–1.22)

0.161

Patient pain VAS in cm*

5.7 (3–8)

5.7 (4.5–8)

6.3 (2.4–7.5)

0.98 (0.89–1.09)

0.694

Physician skin VAS in cm*

1 (0.25–3.4)

1.2 (0.2–3.2)

1 (0.4–5.0)

1.06 (0.96–1.17)

0.241

Patient skin VAS in cm*

4.3 (0.9–7.5)

5.0 (1.2–7.9)

2.4 (0.8–6.3)

0.94 (0.85–1.04)

0.231

Patient fatigue VAS in cm*

6.4 (3.4–8.3)

6.4 (3.5–8.5)

6.5 (3.1–8.3)

1.01 (0.91–1.11)

0.899

MASES*

0 (0–4)

0 (0–3)

3 (0–6)

1.08 (1.02–1.15)

0.013

TJC 0–68*

2 (0–6)

1 (0–4.5)

2 (0.5–6.5)

1.03 (0.98–1.07)

0.228

SJC 0–66*

0 (0–2)

0 (0–2)

1 (0–2.5)

1.01 (0.93–1.08)

0.888

DAPSA*

16.3 (11.4–22.3)

17.1 (11.0–21.7)

15.2 (11.5–24.8)

1.01 (0.98–1.03)

0.643

DAPSA REM/LDA n (%)

23 (41.1)

4 (38.9)

9 (45.0)

1.17 (0.58–2.37)

0.654

HAQ-DI*

1.625 (1.0625–2.050)

1.375 (0.875–1.906)

1.875 (1.250–2.375)

1.94 (1.27–2.97)

0.002

MDA 5/7 n (%)

7 (9.9)

6 (13.6)

1 (3.7)

0.35 (0.06–2.21)

0.265

sDMARD use n (%)

54 (75.0)

32 (71.1)

22 (81.5)

1.47(0.65–3.30)

0.355

bDMARD use n (%)

8 (11.0)

6 (13.0)

2 (7.4)

0.65 (0.19–2.24)

0.496

1.2—Longitudinal data

Sustained DAPSA REM/LDA (≥ 12 months) n (%)

41 (56.2)

26 (56.5)

15 (55.6)

0.98 (0.54–1.78)

0.936

Achieving DAPSA REM/LDA at least once n (%)

70 (95.9)

45 (97.8)

25 (92.6)

0.54 (0.23–1.27)

0.155

ΔDAPSA*

-3.9 (-10.1/ + 2.5)

-3.1 (-9.8/ + 4.6)

-5.0 (-12.9/ + 1.6)

0.98 (0.96 – 1.02)

0.429

Sustained MDA (≥ 12 months) n (%)

15 (20.5)

12 (26.1)

3 (11.1)

0.48 (0.17–1.39)

0.178

Achieving MDA at least once n (%)

45 (61.6)

28 (60.9)

17 (63.0)

1.06 (0.57–1.97)

0.860

sDMARD use ≥ 12 months n (%)

64 (87.7)

38 (82.6)

26 (96.3)

3.66 (0.56–23.7)

0.175

bDMARD use ≥ 12 months n (%)

31 (42.5)

17 (37.0)

14 (51.9)

1.46 (0.80–2.65)

0.214